IP Library › Granted Patent US 12,697,414
Granted Patent B2
US 12,697,414 · App. 18/614,296 · Granted Aug 4, 2026

Adipose compositions and methods of use thereof

Inventor: Alla Danilkovitch (Columbia, MD)
Assignee: BRITECYTE INC.
A61L27/3691
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,697,414
App. No.
18/614,296
Filed
Mar 22, 2024
Granted
Aug 4, 2026
Kind
B2
Art Unit
1653
USPC
424/574
Abstract

Disclosed are devitalized adipose tissue. Disclosed are compositions comprising devitalized adipose tissue. In some aspects, the compositions further comprise a cryopreservation or lyophilization solution. Disclosed are cryopreserved or lyophilized devitalized adipose tissue. Disclosed are methods of augmenting a soft tissue site of a subject in need thereof comprising administering to the subject a composition comprising devitalized adipose tissue. Disclosed are methods of treating a subject having fat pad atrophy comprising administering to the subject a composition comprising devitalized adipose tissue. Disclosed are methods of treating a subject having lipodystrophy comprising administering to the subject a composition comprising devitalized adipose tissue. Disclosed are methods of treating a subject having a metabolic disease or condition comprising administering to the subject a composition comprising devitalized adipose tissue.

Claims (18)

1 . A cryopreserved composition comprising autologous or allogeneic devitalized adipose tissue,

wherein the devitalized adipose tissue comprises at least 50% of native lipids,

wherein the devitalized adipose tissue comprises at least 70% of native growth factors,

wherein the devitalized adipose tissue is not decellularized,

wherein the devitalized adipose tissue retains its native structure,

wherein the composition does not comprise free lipids,

wherein the composition does not comprise TNFα, and

wherein the devitalized adipose tissue comprises less than 5% native viable cells.

2 . The composition of claim 1 , wherein the devitalized adipose tissue is minced.

3 . The composition of claim 2 , wherein the minced devitalized adipose tissue comprises pieces of adipose tissue less than 1 mm in size.

4 . The composition of claim 1 , further comprising a pharmaceutically acceptable carrier.

5 . The composition of claim 1 , further comprising one or more lyopreservative agents.

6 . The composition of claim 5 , wherein the one or more lyopreservative agents is a sugar.

7 . The composition of claim 6 , wherein the sugar is trehalose.

8 . The composition of claim 5 , wherein the one or more lyopreservative agents is human serum albumin.

9 . The composition of claim 1 , wherein the devitalized adipose tissue comprises less than 5%, 2%, 1%, 0.5%, 0.2%, 0.1%, 0.05% or 0.01% peroxidized lipids of total lipids.

10 . The composition of claim 1 , wherein the growth factors are angiogenic growth factors, vascular endothelial growth factors, insulin like growth factors, hepatocyte growth factor, platelet-derived growth factor, or fibroblast growth factors.

11 . The composition of claim 1 , wherein the devitalized adipose tissue is non-radiated.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 3, 2026
From: DANILKOVITCH, ALLA
To: BRITECYTE INC.
Reel/Frame 074839/0694 →
Continuity (3)
Continuation 17887013 · Aug 12, 2022
Provisional Application 63232465 · Aug 12, 2021
Related Publication 20240261471A1 · Aug 8, 2024
References Cited (53)
US 7890183B2 · Palti · 2011 [cited by applicant]
US 10596201B2 · Huang · 2020 [cited by applicant]
US 20080195230A1 · Quijano · 2008 [cited by applicant]
US 20100279405A1 · Peterson · 2010 [cited by examiner]
US 20110008300A1 · Wouters · 2011 [cited by examiner]
US 20110151011A1 · Flynn · 2011 [cited by applicant]
US 20120264190A1 · Christman · 2012 [cited by applicant]
US 20140234272A1 · Vesey · 2014 [cited by applicant]
US 20150044179A1 · Saeki · 2015 [cited by applicant]
US 20160101200A1 · Chitre · 2016 [cited by examiner]
US 20170021058A1 · Huang et al. · 2017 [cited by applicant]
US 20180117088A1 · Cao et al. · 2018 [cited by applicant]
US 20180127719A1 · Nahas et al. · 2018 [cited by applicant]
US 20190076582A1 · Connor · 2019 [cited by applicant]
US 20190111183A1 · Xu · 2019 [cited by applicant]
US 20190298885A1 · Schilling · 2019 [cited by applicant]
US 20220032934A1 · Zhang · 2022 [cited by applicant]
US 20220073881A1 · Nahas · 2022 [cited by applicant]
US 20220339196A1 · Rho et al. · 2022 [cited by applicant]
US 20230044236A1 · Kim · 2023 [cited by applicant]
US 20230063467A1 · Danilkovitch · 2023 [cited by applicant]
US 20240261471A1 · Danilkovitch · 2024 [cited by applicant]
CA 3223186 · 2022 [cited by applicant]
EP 4370140 · 2022 [cited by applicant]
WO WO2021045595A1 · 2021 [cited by applicant]
WO PCTUS2236982 · 2022 [cited by applicant]
WO WO2023287892A1 · 2023 [cited by applicant]
Cheung et al.,Composite hydrogel scaffolds incorporating decellularized adipose tissue for soft tissue engineering with adipose-derived stem cells, Biomaterials, vol. 35, (2014), pp. 1914-1923. [cited by examiner]
Bush-Joseph et al., Effect of Tibial Attachment Location on the Healing of the Anterior Cruciate Ligament Freeze Model, Journal of Orthopaedic Research, vol. 14, (1996), pp. 534-541. [cited by examiner]
Flynn,The use of decellularized adipose tissue to provide an inductive microenvironment for the adipogenic differentiation of human adipose-derived stem cells, Biomaterials, vol. 31, (2010), pp. 4715-4724. [cited by examiner]
Yang et al., Role of Anti-TNF-α Therapy in Fat Graft Preservation, Annals of Plastic Surgery, vol. 68, No. 5, (2012), pp. 531-535. [cited by examiner]
U.S. Appl. No. 17/887,013, filed Aug. 12, 2022, Danilkovitch. [cited by applicant]
U.S. Appl. No. 63/232,465, filed Aug. 12, 2021, Danilkovitch. [cited by applicant]
U.S. Appl. No. 18/578,959, filed Jul. 13, 2022, Danilkovitch. [cited by applicant]
U.S. Appl. No. 63/221,248, filed Jul. 17, 2022, Danilkovitch. [cited by applicant]
International Search Report and Written Opinion mailed on Oct. 5, 2022 by International Searching Authority for Patent Application No. PCT/US22/36982, which was filed on Jul. 13, 2022 (Inventor—Danilkovitch et al.; Appl… [cited by applicant]
Rossi. “Decoration of RGD-mimetic porous scaffold with engineered, devitalized adipose matrix.” Acta Biomaterialia. Dec. 18, 2016, p. 192. [cited by applicant]
Kim, D.Y., et al., “Cryopreservation of lipoaspirates: in vitro measurement of the viability of adipose-derived stem cell and lipid peroxidation,” Int. Wound J., pp. 1-9 (2020). [cited by applicant]
Menzi, N., et al., Wet milling of large quantities of human excision adipose tissue for the isolation of stromal vascular fraction cells, Cytotechnology, 70: 807-817 (2018). [cited by applicant]
Osinga, R., et al., “Effects of Intersyringe Processing on Adipose Tissue and Its Cellular Components: Implications in Autologous Fat Grafting,” Plastic and Reconstructive Surgery, 135(6): 1618 (2015). [cited by applicant]
Rao, P., et al., “Structural and Functional Characterization of Deceased Donor Stem Cells: A Viable Alternative to Living Donor Stem Cells,” Hindawi, Stem Cells International, 13 Pages (2019). [cited by applicant]
Schafer, M.E., et al., “Acute Adipocyte Viability After Third-Generation Ultrasound-Assisted Liposuction,” Aesthetic Surgery Journal, 33(5): 698-704 (2013). [cited by applicant]
Urbonas, T., et al., “Assessing Adipocyte Viability and Surgeons' Work Efficiency by Comparing Different Liposuction Methods,” Plastic Reconstr. Surg. Glob. Open, 9 Pages (2023). [cited by applicant]
Chun, S.Y., et al., “Optimization of extracellular matrix extraction from human perirenal adipose tissue,” Journal of Biomaterials (2021). [cited by applicant]
Chun, S.Y., et al., “Optimal delipidation solvent to secure extracellular matrix from human perirenal adipose tissue,” Journal of Biomedical Materials Research, (2021). [cited by applicant]
Vargel, I., et al., “Autologous Adipose-Derived Tissue Stromal Vascular Fraction (AD-tSVF) for Knee Osteoarthritis,” Int. J. Mol. Sci., 23: 13517 (2022), 32 Pages. [cited by applicant]
Wang, J.K., et al., “Supercritical carbon dioxide extracted extracellular matrix material from adipose tissue,” Materials Science and Engineering, C75: 349-358 (2017). [cited by applicant]
Wu, I., et al., “An Injectable Adipose Matrix for Soft Tissue Reconstruction,” 129(6): 1247-1257 (2012). [cited by applicant]
Flynn, L.E., “The use of decellularized adipose tissue to provide an inductive microenvironment for the adipogenic differentiation of human adipose-derived stem cells,” Biomaterials, 31(17): 4715-4724 (2010). [cited by applicant]
Guo, L., et al., “Comparison of adipose tissue cellularity in chicken lines divergently selected for Fatness,” Poultry Science, 90(9): 2024-2034 (2010). [cited by applicant]
Moon, J., et al., “Brown adipose tissue ameliorates autoimmune arthritis via inhibition of Th17 cells,” Scientific Reports, 10:12374 (2020). [cited by applicant]
Niazli, N., “Autologous Micro Fragmented Adipose Cell Therapy for End-Stage Ankle Osteoarthritis-Case Report and Review of Literature,” SN Comprehensive Clinical Medicine, 3: 909-913 (2021). [cited by applicant]
Wang, L., et al., “Combining decellularized human adipose tissue extracellular matrix and adipose-derived stem cells for adipose tissue engineering,” Acta Biomaterialia, 9(11):8921-8931 (2013). [cited by applicant]